(HPOL-B) HEXPOL (publ) - Ratings and Ratios
Rubber Compounds, Thermoplastic Compounds, Gaskets, Seals, Wheels
HPOL-B EPS (Earnings per Share)
HPOL-B Revenue
Description: HPOL-B HEXPOL (publ)
HEXPOL AB (publ) is a leading developer, manufacturer, and supplier of various polymer compounds and engineered products, serving a diverse range of industries, including automotive, aerospace, construction, and consumer goods. The company operates through two main segments: HEXPOL Compounding, which produces rubber and thermoplastic compounds, and HEXPOL Engineered Products, which manufactures gaskets, seals, and wheels.
The companys product portfolio is diverse, with a range of brands catering to different markets, such as HEXFLAME, HEXLIGHT, and Dryflex. HEXPOLs customers include manufacturers of medical equipment, plate heat exchangers, forklifts, and castor wheels, among others. With a history dating back to 1893, the company has established a strong presence in Europe, the Americas, and Asia.
To evaluate HEXPOLs performance, key performance indicators (KPIs) such as revenue growth, operating margin, and return on equity (RoE) can be analyzed. With a RoE of 14.43%, the company demonstrates a decent return on shareholders equity. Additionally, the companys market capitalization stands at approximately 31.9 billion SEK, indicating a significant market presence. Further analysis of KPIs such as debt-to-equity ratio, interest coverage ratio, and dividend yield can provide a more comprehensive understanding of the companys financial health and investment potential.
From a valuation perspective, HEXPOLs price-to-earnings (P/E) ratio of 14.69 suggests a relatively moderate valuation compared to its earnings. However, a more detailed analysis of the companys earnings quality, growth prospects, and industry comparables is necessary to determine if the stock is fairly valued. By examining these factors, investors can make a more informed decision about the attractiveness of HEXPOL as an investment opportunity.
HPOL-B Stock Overview
| Market Cap in USD | 3,048m |
| Sub-Industry | Specialty Chemicals |
| IPO / Inception |
HPOL-B Stock Ratings
| Growth Rating | -6.13% |
| Fundamental | 57.8% |
| Dividend Rating | 70.1% |
| Return 12m vs S&P 500 | -32.5% |
| Analyst Rating | - |
HPOL-B Dividends
| Dividend Yield 12m | 4.62% |
| Yield on Cost 5y | 7.36% |
| Annual Growth 5y | 5.46% |
| Payout Consistency | 96.9% |
| Payout Ratio | 67.6% |
HPOL-B Growth Ratios
| Growth Correlation 3m | -61.5% |
| Growth Correlation 12m | -81.6% |
| Growth Correlation 5y | 52.9% |
| CAGR 5y | 8.42% |
| CAGR/Max DD 5y | 0.21 |
| Sharpe Ratio 12m | -0.38 |
| Alpha | -30.26 |
| Beta | 0.505 |
| Volatility | 28.18% |
| Current Volume | 443.2k |
| Average Volume 20d | 376.7k |
| Stop Loss | 82.8 (-3%) |
| Signal | 0.00 |
Piotroski VR‑10 (Strict, 0-10) 5.0
| Net Income (2.05b TTM) > 0 and > 6% of Revenue (6% = 1.20b TTM) |
| FCFTA 0.09 (>2.0%) and ΔFCFTA -1.42pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue -5.41% (prev 1.57%; Δ -6.99pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.10 (>3.0%) and CFO 2.44b > Net Income 2.05b (YES >=105%, WARN >=100%) |
| Net Debt (-1.12b) to EBITDA (2.49b) ratio: -0.45 <= 3.0 (WARN <= 3.5) |
| Current Ratio 0.87 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (344.4m) change vs 12m ago 0.00% (target <= -2.0% for YES) |
| Gross Margin 21.07% (prev 22.50%; Δ -1.43pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 83.31% (prev 88.68%; Δ -5.37pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 12.25 (EBITDA TTM 2.49b / Interest Expense TTM 169.0m) >= 6 (WARN >= 3) |
Altman Z'' 3.32
| (A) -0.04 = (Total Current Assets 7.02b - Total Current Liabilities 8.10b) / Total Assets 24.34b |
| (B) 0.46 = Retained Earnings (Balance) 11.26b / Total Assets 24.34b |
| (C) 0.09 = EBIT TTM 2.07b / Avg Total Assets 24.07b |
| (D) 1.45 = Book Value of Equity 15.33b / Total Liabilities 10.54b |
| Total Rating: 3.32 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 57.79
| 1. Piotroski 5.0pt = 0.0 |
| 2. FCF Yield 6.96% = 3.48 |
| 3. FCF Margin 11.50% = 2.88 |
| 4. Debt/Equity 0.38 = 2.43 |
| 5. Debt/Ebitda 2.11 = -0.21 |
| 6. ROIC - WACC 3.56% = 4.45 |
| 7. RoE 13.83% = 1.15 |
| 8. Rev. Trend -71.74% = -3.59 |
| 9. Rev. CAGR -5.98% = -1.00 |
| 10. EPS Trend -48.25% = -1.21 |
| 11. EPS CAGR -4.81% = -0.60 |
What is the price of HPOL-B shares?
Over the past week, the price has changed by +0.47%, over one month by -0.93%, over three months by -4.42% and over the past year by -21.33%.
Is HEXPOL (publ) a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of HPOL-B is around 78.56 SEK . This means that HPOL-B is currently overvalued and has a potential downside of -8.01%.
Is HPOL-B a buy, sell or hold?
What are the forecasts/targets for the HPOL-B price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 102.6 | 20.1% |
| Analysts Target Price | - | - |
| ValueRay Target Price | 86.2 | 1% |
HPOL-B Fundamental Data Overview
Market Cap SEK = 29.00b (29.00b SEK * 1.0 SEK.SEK)
CCE Cash And Equivalents = 1.12b SEK (last quarter)
P/E Trailing = 14.1275
P/S = 1.4465
P/B = 2.0827
Beta = 0.953
Revenue TTM = 20.05b SEK
EBIT TTM = 2.07b SEK
EBITDA TTM = 2.49b SEK
Long Term Debt = 700.0m SEK (from longTermDebt, last quarter)
Short Term Debt = 4.54b SEK (from shortTermDebt, last quarter)
Debt = 5.24b SEK (Calculated: Short Term 4.54b + Long Term 700.0m)
Net Debt = -1.12b SEK (from netDebt column, last quarter)
Enterprise Value = 33.13b SEK (29.00b + Debt 5.24b - CCE 1.12b)
Interest Coverage Ratio = 12.25 (Ebit TTM 2.07b / Interest Expense TTM 169.0m)
FCF Yield = 6.96% (FCF TTM 2.31b / Enterprise Value 33.13b)
FCF Margin = 11.50% (FCF TTM 2.31b / Revenue TTM 20.05b)
Net Margin = 10.23% (Net Income TTM 2.05b / Revenue TTM 20.05b)
Gross Margin = 21.07% ((Revenue TTM 20.05b - Cost of Revenue TTM 15.82b) / Revenue TTM)
Tobins Q-Ratio = 2.16 (Enterprise Value 33.13b / Book Value Of Equity 15.33b)
Interest Expense / Debt = 0.76% (Interest Expense 40.0m / Debt 5.24b)
Taxrate = 26.02% (from yearly Income Tax Expense: 781.0m / 3.00b)
NOPAT = 1.53b (EBIT 2.07b * (1 - 26.02%))
Current Ratio = 0.87 (Total Current Assets 7.02b / Total Current Liabilities 8.10b)
Debt / Equity = 0.38 (Debt 5.24b / last Quarter total Stockholder Equity 13.80b)
Debt / EBITDA = 2.11 (Net Debt -1.12b / EBITDA 2.49b)
Debt / FCF = 2.27 (Debt 5.24b / FCF TTM 2.31b)
Total Stockholder Equity = 14.83b (last 4 quarters mean)
RoA = 8.43% (Net Income 2.05b, Total Assets 24.34b )
RoE = 13.83% (Net Income TTM 2.05b / Total Stockholder Equity 14.83b)
RoCE = 13.32% (Ebit 2.07b / (Equity 14.83b + L.T.Debt 700.0m))
RoIC = 10.32% (NOPAT 1.53b / Invested Capital 14.83b)
WACC = 6.76% (E(29.00b)/V(34.25b) * Re(7.88%)) + (D(5.24b)/V(34.25b) * Rd(0.76%) * (1-Tc(0.26)))
Shares Correlation 5-Years: 94.90 | Cagr: 0.00%
Discount Rate = 7.88% (= CAPM, Blume Beta Adj.) -> floored to rf + ERP 8.05%
[DCF Debug] Terminal Value 78.20% ; FCFE base≈2.42b ; Y1≈2.40b ; Y5≈2.52b
Fair Price DCF = 135.3 (DCF Value 44.62b / Shares Outstanding 329.7m; 5y FCF grow -1.34% → 3.0% )
Revenue Correlation: -71.74 | Revenue CAGR: -5.98%
Rev Growth-of-Growth: 3.95
EPS Correlation: -48.25 | EPS CAGR: -4.81%
EPS Growth-of-Growth: -11.95